Literature DB >> 25249257

Clinicopathological significance of CXCR4 expression in renal cell carcinoma: a meta-analysis.

Bo Tang1, Fang Tang, Yang Li, Shengguang Yuan, Bo Li, Zhenran Wang, Songqing He.   

Abstract

BACKGROUND: Emerging evidence indicates that C-X-C chemokine receptor type 4 (CXCR4) is a candidate oncogene in several types of human tumors including renal cell carcinoma (RCC). We conducted a meta-analysis to quantitatively evaluate the association of CXCR4 expression with the incidence of RCC and clinicopathological characteristics.
METHODS: We searched PubMed, Embase, and ISI Web of Knowledge to identify studies written in English. Methodological quality of the studies was also evaluated. Odds ratio and hazard ratio were calculated and summarized.
RESULTS: Final analysis was performed of 994 RCC patients from 11 eligible studies. We observed that CXCR4 expression was significantly higher in RCC than in normal renal tissues. CXCR4 expression was not found to be associated with sex status or clinical staging. However, CXCR4 expression was clearly associated with Fuhrman grading, metastatic status, and overall survival in RCC patients.
CONCLUSIONS: The results of this meta-analysis suggest that CXCR4 expression is associated with an increased risk and worsen survival in RCC patients. The aberrant CXCR4 expression plays an important role in the carcinogenesis and metastasis of RCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25249257     DOI: 10.1245/s10434-014-4019-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Authors:  Yozo Mitsui; Hiroaki Shiina; Taku Kato; Shigekatsu Maekawa; Yutaka Hashimoto; Marisa Shiina; Mitsuho Imai-Sumida; Priyanka Kulkarni; Pritha Dasgupta; Ryan Kenji Wong; Miho Hiraki; Naoko Arichi; Shinichiro Fukuhara; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Guoren Deng; Rajvir Dahiya; Koichi Nakajima; Yuichiro Tanaka
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

2.  Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis.

Authors:  Yong-Jiang Li; Yi-Ling Dai; Wen-Biao Zhang; Shuang-Jiang Li; Chong-Qi Tu
Journal:  Clin Exp Med       Date:  2015-12-17       Impact factor: 3.984

3.  CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.

Authors:  Andreas Krieg; Jasmin C Riemer; Leila A Telan; Helmut E Gabbert; Wolfram T Knoefel
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

4.  Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma.

Authors:  Milena Potić Floranović; Ana Ristić Petrović; Filip Veličković; Ljubinka Janković Veličković
Journal:  Clin Exp Nephrol       Date:  2021-06-09       Impact factor: 2.801

Review 5.  The Role of CXCL12 in Kidney Diseases: A Friend or Foe?

Authors:  Anni Song; Anni Jiang; Wei Xiong; Chun Zhang
Journal:  Kidney Dis (Basel)       Date:  2021-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.